Table 1.
IPATASERTIB (IPATential150) versus CAPIVASERTIB (ProCAID) in prostate cancer.
| IPATASERTIB | CAPIVASERTIB | |
|---|---|---|
| Clinical trial | IPATential | ProCAID |
| Phase | III | II |
| Number of patients enrolled | 1101 | 150 |
| Primary endpoint | rPFS | cPFS |
| Stage of the disease | mCRPC | mCRPC |
| Association to AKTi | Abiraterone + Prednisolone | Docetaxel + Prednisolone |
| Control | Placebo | Placebo |
| Primary outcome’s HR | 0.77 (95% CI, 0.61–0.98); p = 0.034 | 0.92 (80% CI, 0.73–1.16); p = 0.32 |
| Grade ≥ 3 adverse events | 70% | 62% |
| AEs leading to treatment discontinuation | 21% | 23% |
rPFS: radiological progression-free survival; cPFS: composite radiological progression-free survival; AKTi: AKT inhibitor; mCRPC: metastatic castration resistant prostate cancer, HR: Hazard Ratio; AEs: adverse events.